BACKGROUND: To evaluate the efficacy of Endo-Bronchial Valves in the management of persistent air-leaks (PALs) and the procedural cost. METHODS: It was a retrospective multicenter study including consecutive patients with PALs for alveolar pleural fistula (APF) undergoing valve treatment. We assessed the efficacy and the cost of the procedure. RESULTS: Seventy-four patients with persistent air leaks due to various etiologies were included in the analysis. In all cases the air leaks were severe and refractory to standard treatments. Sixty-seven (91%) patients underwent valve treatment obtaining a complete resolution of air-leaks in 59 (88%) patients; a reduction of air-leaks in 6 (9%); and no benefits in 2 (3%). The comparison of data before and after valve treatment showed a significant reduction of air-leak duration (16.2±8.8 versus 5.0±1.7 days; P<0.0001); chest tube removal (16.2±8.8 versus 7.3±2.7 days; P<0.0001); and length of hospital stay (LOS) (16.2±8.8 versus 9.7±2.8 days; P=0.004). Seven patients not undergoing valve treatment underwent pneumo-peritoneum with pleurodesis (n=6) or only pleurodesis (n=1). In only 1 (14%) patient, the chest drainage was removed 23 days later while the remaining 6 (86%) were discharged with a domiciliary chest drainage removed after 157±41 days. No significant difference was found in health cost before and after endobronchial valve (EBV) implant (P=0.3). CONCLUSIONS: Valve treatment for persistent air leaks is an effective procedure. The reduction of hospitalization costs related to early resolution of air-leaks could overcome the procedural cost.
BACKGROUND: To evaluate the efficacy of Endo-Bronchial Valves in the management of persistent air-leaks (PALs) and the procedural cost. METHODS: It was a retrospective multicenter study including consecutive patients with PALs for alveolar pleural fistula (APF) undergoing valve treatment. We assessed the efficacy and the cost of the procedure. RESULTS: Seventy-four patients with persistent air leaks due to various etiologies were included in the analysis. In all cases the air leaks were severe and refractory to standard treatments. Sixty-seven (91%) patients underwent valve treatment obtaining a complete resolution of air-leaks in 59 (88%) patients; a reduction of air-leaks in 6 (9%); and no benefits in 2 (3%). The comparison of data before and after valve treatment showed a significant reduction of air-leak duration (16.2±8.8 versus 5.0±1.7 days; P<0.0001); chest tube removal (16.2±8.8 versus 7.3±2.7 days; P<0.0001); and length of hospital stay (LOS) (16.2±8.8 versus 9.7±2.8 days; P=0.004). Seven patients not undergoing valve treatment underwent pneumo-peritoneum with pleurodesis (n=6) or only pleurodesis (n=1). In only 1 (14%) patient, the chest drainage was removed 23 days later while the remaining 6 (86%) were discharged with a domiciliary chest drainage removed after 157±41 days. No significant difference was found in health cost before and after endobronchial valve (EBV) implant (P=0.3). CONCLUSIONS: Valve treatment for persistent air leaks is an effective procedure. The reduction of hospitalization costs related to early resolution of air-leaks could overcome the procedural cost.
Authors: Christophe A Dooms; Herbert Decaluwe; Jonas Yserbyt; Paul De Leyn; Dirk Van Raemdonck; Vincent Ninane Journal: Eur Respir J Date: 2013-11-14 Impact factor: 16.671
Authors: Mario Santini; Alfonso Fiorelli; Giovanni Vicidomini; Vincenzo Giuseppe Di Crescenzo; Gaetana Messina; Paolo Laperuta Journal: Eur J Cardiothorac Surg Date: 2011-07-20 Impact factor: 4.191
Authors: Irene Firlinger; Elisabeth Stubenberger; Michael Rolf Müller; Otto C Burghuber; Arschang Valipour Journal: Ann Thorac Surg Date: 2013-02-21 Impact factor: 4.330
Authors: Colin T Gillespie; Daniel H Sterman; Robert J Cerfolio; Daniel Nader; Michael S Mulligan; Richard A Mularski; Ali I Musani; John C Kucharczuk; H Xavier Gonzalez; Steven C Springmeyer Journal: Ann Thorac Surg Date: 2011-01 Impact factor: 4.330
Authors: John M Travaline; Robert J McKenna; Tiziano De Giacomo; Federico Venuta; Steven R Hazelrigg; Mark Boomer; Gerard J Criner Journal: Chest Date: 2009-04-06 Impact factor: 9.410
Authors: Rene S Bermea; Joseph Miller; W Wyatt Wilson; Karen Dugan; Laura Frye; Septimiu Murgu; D Kyle Hogarth Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405
Authors: Muhanned Abu-Hijleh; Kim Styrvoky; Vikram Anand; Fernando Woll; Lonny Yarmus; Michael S Machuzak; Daniel A Nader; Timothy W Mullett; D Kyle Hogarth; Jennifer W Toth; Ghazwan Acash; Roberto F Casal; Stephen Hazelrigg; Douglas E Wood Journal: Lung Date: 2019-08-28 Impact factor: 2.584